The HCCS Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the HCCS gene has been disrupted within the A-549 human lung adenocarcinoma epithelial cell line. This polyclonal format provides a genetically diverse pool of knockout cells, minimizing clonal artifact and enabling reproducible interrogation of HCCS loss-of-function phenotypes. The product is optimized for rigorous investigation of mitochondrial biology and apoptosis in a widely used model of non-small cell lung cancer (NSCLC).
The parental A-549 cell line was established from the lung adenocarcinoma of a 58-year-old Caucasian male and displays adherent epithelial morphology. It is extensively employed in biomedical research to study NSCLC biology, drug responses, viral pathogenesis, and toxicological mechanisms. Its robust growth characteristics and well-documented signaling networks make it an ideal background for CRISPR-based gene knockout, facilitating the dissection of gene function in a disease-relevant setting.
HCCS encodes the enzyme holocytochrome c synthase, which catalyzes the essential covalent attachment of heme to apocytochrome c (CYCS), generating mature holocytochrome c. This reaction is indispensable for mitochondrial electron transfer and intrinsic apoptosis. HCCS activity is transcriptionally regulated by PGC-1?? and NRF1 in response to mitochondrial biogenesis cues, while heme availability serves as a direct substrate-level control. Mature cytochrome c then mediates electron shuttling between ubiquinol-cytochrome c reductase (Complex III, component UQCRC1) and cytochrome c oxidase (Complex IV, component COX4I1), sustaining oxidative phosphorylation. Additionally, cytochrome c release from mitochondria promotes assembly of the apoptosome, comprising APAF1 and procaspase-9, which activates CASP9 and downstream CASP3. The BCL2 family members dictate the permeability of the outer mitochondrial membrane, thereby governing this release. HCCS thus operates at a critical nexus, interacting with CYCS, heme, and mitochondrial import chaperones to coordinate energy metabolism and cell death.
Disruption of HCCS in the A-549 lung adenocarcinoma context produces a profound dual phenotype of metabolic insufficiency and apoptosis dysregulation. Abrogation of holocytochrome c synthesis severely depresses mitochondrial respiratory capacity and ATP output, mimicking metabolic adaptations observed in certain NSCLC tumors. Concomitantly, the loss of cytochrome c-mediated caspase activation impairs intrinsic apoptotic signaling, potentially contributing to chemoresistance. This knockout model therefore allows researchers to examine how mitochondrial fidelity and cell death avoidance cooperate to drive lung cancer aggressiveness and therapeutic failure.
The HCCS Knockout A-549 Polyclonal Cells are a versatile resource for diverse experimental strategies. Mitochondrial function can be directly assayed using Seahorse respirometry, ATP quantification, and Complex IV activity measurements, while apoptosis is readily monitored via Annexin V staining, caspase-3/9 activation assays, and cytochrome c release profiling. Gene expression changes and protein levels can be validated by RT-qPCR and Western blotting. Moreover, these cells support drug screening efforts for mitochondrial-targeted therapies, apoptosis sensitizers, and investigation of MLS syndrome or other heme-related disorders. The polyclonal nature ensures robust, batch-to-batch consistency for both mechanistic studies and high-throughput pharmacological assays.
